Oncology

  • 6 February 2019
    News

    Xencor and Genentech partner on novel IL-15 cytokine drugs

    Monoclonal antibody engineering company Xencor has signed a licensing and research partnership with Roche Group member Genentech to develop and commercialise the former’s lead cytokine product XmAB2403, an IL-15/IL-15 receptor...

  • 5 February 2019
    Comment

    Young adults with cancer need clinical pathways

    Patients ages 15–39, having transitioned from the end of childhood into adulthood but without joining the heavily studied “older patient” demographic, tend to get stuck in a treatment impasse.

Close
Close
Close

Go Top